Search - tctmd.com

Displaying 41 - 60 of 80

Sort: Relevancy | Date

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

Seasonal, but No Year-round, Protection With Flu Shots in HF: IVVE

News Conference News ACC 2022

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

Yael L. Maxwell

April 03, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

L.A. McKeown

April 02, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

Todd Neale

May 18, 2021

News Conference News ACC 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

Todd Neale

May 17, 2021

Presentation ACC 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presenter: Adam DeVore

May 17, 2021

Presentation ACC 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presenter: Deepak L. Bhatt

May 17, 2021

News Conference News ACC 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

Caitlin E. Cox

May 16, 2021

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Shelley Wood

May 16, 2021

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Daily News ACC 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Shelley Wood

March 17, 2020

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

Advertisement

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

‘Enormous’ QoL Improvements With Mavacamten in HCM

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content